In particular, the new indication covers adult patients needing supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation.
Olumiant first won FDA approval in 2018 for treating moderately-to-severely active rheumatoid arthritis.
Lilly began testing the drug in hospitalized COVID-19 patients in June 2020. It won emergency use authorization (EUA) for such patients in November of that same year when used with remdesivir.
FDA broadened the EUA in July 2021 to allow its use with or without remdesivir.
Olumiant is the first immunomodulatory therapy to score FDA approval for a COVID-19 indication.
The drug continues to be avail…